engleski

Consumption of polyvalent immunoglobulins according to indications

Polyvalent immunoglobulins (IGs), both intravenous (IVIG) and subcutaneous (SCIG), are used in the replacement therapy for primary immunodeficiency and in immunomodulating treatment of autoimmune diseases and neuroimmunological disorders. In the last decades, indications have been extended to secondary immunodeficiency, especially to haematological diseases such, as lymphoproliferative diseases (LPDs) and multiple myeloma (MM). Furthermore, IG are used for iatrogenic hypogammaglobulinemia due to immunotherapy (e.g. Rituximab), in immunosuppressive therapies (steroids, sulfasalazine, mycophenolate mofetil) and bone marrow (BMT) or solid organ transplantation. In clinical usage, when there is a lack of scientifically proven benefit, IG therapy is applied off-label. Aims: The aim of this study is to retrospectively analyze the usage of IG according to the indications.

Polyvalent immunoglobulins ; indication

nije evidentirano